A detailed history of Federated Hermes, Inc. transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Federated Hermes, Inc. holds 3,178 shares of RCUS stock, worth $50,561. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,178
Holding current value
$50,561
% of portfolio
0.0%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$13.69 - $18.01 $43,506 - $57,235
3,178 New
3,178 $48,000
Q3 2023

Nov 13, 2023

SELL
$17.62 - $23.54 $674,370 - $900,946
-38,273 Reduced 97.22%
1,095 $19,000
Q2 2023

Aug 14, 2023

BUY
$16.97 - $22.03 $592,507 - $769,177
34,915 Added 784.08%
39,368 $799,000
Q1 2023

May 08, 2023

BUY
$15.96 - $23.15 $35,159 - $50,999
2,203 Added 97.91%
4,453 $81,000
Q4 2022

Feb 13, 2023

BUY
$19.7 - $35.71 $2,482 - $4,499
126 Added 5.93%
2,250 $46,000
Q3 2022

Nov 14, 2022

BUY
$23.23 - $30.07 $49,340 - $63,868
2,124 New
2,124 $56,000
Q2 2022

Aug 15, 2022

SELL
$17.23 - $37.73 $61,011 - $133,601
-3,541 Closed
0 $0
Q1 2022

May 13, 2022

SELL
$28.92 - $41.83 $293,162 - $424,030
-10,137 Reduced 74.11%
3,541 $111,000
Q4 2021

Feb 14, 2022

BUY
$31.38 - $48.47 $257,472 - $397,696
8,205 Added 149.92%
13,678 $553,000
Q3 2021

Nov 15, 2021

BUY
$26.93 - $37.68 $140,493 - $196,576
5,217 Added 2037.89%
5,473 $191,000
Q2 2021

Aug 16, 2021

SELL
$22.75 - $35.77 $4.3 Million - $6.77 Million
-189,137 Reduced 99.86%
256 $7,000
Q1 2021

May 13, 2021

BUY
$26.16 - $41.39 $4.94 Million - $7.82 Million
188,881 Added 36890.82%
189,393 $5.32 Million
Q4 2020

Feb 12, 2021

SELL
$17.0 - $32.36 $1.99 Million - $3.78 Million
-116,773 Reduced 99.56%
512 $13,000
Q3 2020

Nov 12, 2020

BUY
$17.14 - $25.47 $1.12 Million - $1.66 Million
65,060 Added 124.58%
117,285 $2.01 Million
Q2 2020

Aug 13, 2020

SELL
$13.97 - $36.56 $631,192 - $1.65 Million
-45,182 Reduced 46.38%
52,225 $1.29 Million
Q1 2020

May 13, 2020

BUY
$8.78 - $19.28 $801,693 - $1.76 Million
91,309 Added 1497.36%
97,407 $1.35 Million
Q4 2019

Feb 14, 2020

SELL
$7.33 - $10.79 $2,983 - $4,391
-407 Reduced 6.26%
6,098 $62,000
Q3 2019

Nov 14, 2019

SELL
$6.44 - $10.18 $528 - $834
-82 Reduced 1.24%
6,505 $59,000
Q2 2019

Aug 14, 2019

BUY
$7.29 - $13.38 $6,123 - $11,239
840 Added 14.62%
6,587 $53,000
Q1 2019

May 10, 2019

BUY
$8.95 - $12.49 $18,240 - $25,454
2,038 Added 54.95%
5,747 $72,000
Q4 2018

Feb 13, 2019

SELL
$9.74 - $14.5 $2,259 - $3,364
-232 Reduced 5.89%
3,709 $39,000
Q3 2018

Nov 13, 2018

BUY
$10.88 - $14.95 $42,878 - $58,917
3,941 New
3,941 $55,000

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.15B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Federated Hermes, Inc. Portfolio

Follow Federated Hermes, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Federated Hermes, Inc. with notifications on news.